MedTrace Logo

A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

NCT05225324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 702

Last updated 2025-06-22

No results posted yet for this study

Summary

The purpose of this study is to describe the following in relation to the safety of Equfina Tablet 50 mg in the post marketing setting: 1. Serious adverse events (SAEs) and adverse drug reactions (ADRs) 2. Unexpected adverse events (AEs) and ADRs not reflected in the precautions for use 3. Known ADRs 4. Non-serious ADRs 5. Other safety and efficacy related information.

Conditions

  • Parkinson Disease

Interventions

DRUG

Equfina 50 mg

Equfina 50 mg tablets.

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-03
Primary Completion
2025-03-20
Completion
2025-03-20
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225324 on ClinicalTrials.gov